Skip to content
http://lifestyle.lmcordoba.com.ar/
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
LB Pharmaceuticals Inc
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026
LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
June 30, 2026
LB Pharmaceuticals to Participate in Upcoming June Investor Events
May 28, 2026
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 24, 2026
LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
May 21, 2026
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
March 27, 2026
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia
March 25, 2026
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
March 9, 2026
LB Pharmaceuticals to Participate in Upcoming March Investor Events
March 4, 2026
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2026
1
2
Next Page
→